Elizabeth Cormier-May studied organic chemistry at Wheaton College and attended graduate school for organic chemistry and chemical biology at Northeastern University. She built her career launching and selling diagnostic tests into the women’s health, oncology, and urology markets. Since then, Elizabeth has worked with several MDx firms such as Myriad Genetics, Qiagen, and Predictive Biosciences, as well as in companion diagnostic development with pharmaceutical companies.
In spring 2016, Elizabeth Cormier-May started to work for Exosome Diagnostics, a privately held U.S. molecular diagnostic company based in Cambridge, MA. Elizabeth collaborated with the company helping to build infrastructure for the launch of Exosome’s flagship test, ExoDx Prostate (IntelliScore). In September 2016, Exosome Diagnostics appointed Elizabeth as its head of commercial diagnostics.
In February 2021, Mammogen, Inc. and Bench International appointed Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. The company is working on detecting earlier, diagnosing easier, treating better, and supporting all women throughout the life-long battle that comes with survivorship.
Mammogen’s core technology is a non-invasive screening solution intended for all women, but particularly for the under-40 population who aren’t eligible for annual mammography and the 55+ population who are only recommended for mammography every other year.
Cormier-May has accumulated several years of experience in medicinal chemistry, genetics, and companion and molecular diagnostics development.
